CD278

MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020

Retrieved on: 
Sunday, September 20, 2020
CD278

A total of 28 patients were treated at doses 3.0 mg/kg administered every three weeks initially.

Key Points: 
  • A total of 28 patients were treated at doses 3.0 mg/kg administered every three weeks initially.
  • In addition, dose-dependent upregulation of the inducible costimulator (ICOS) molecule was evident in treated patients, including those who responded to MGD019 therapy.
  • In addition, we are very pleased that MGD019 was well tolerated, said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.
  • These results are available on-demand as part of the ESMO Virtual Congress 2020 Proffered Paper - Investigational Immunotherapy session on September 20, 2020 (Presentation # 1020O).

Alpine Immune Sciences Announces Poster Presentations at EULAR 2020

Retrieved on: 
Friday, May 29, 2020
Research, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Medical specialties, Medicine, Immunology, CD278, Co-stimulation, T cell, Immunotherapy, Autoimmunity, ALPN-101, Alpine Immune Sciences, Inc.

An abstract of the presentation will be available on the EULAR E-Congress 2020.

Key Points: 
  • An abstract of the presentation will be available on the EULAR E-Congress 2020.
  • CD28 and ICOS are closely related costimulatory molecules with partially overlapping roles in T cell activation likely playing a role in multiple autoimmune and inflammatory diseases.
  • Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics, creating potentially powerful multifunctional immunotherapies to improve patients lives via unique protein engineering technologies.
  • Alpine is backed by world-class research and development capabilities, a highly productive scientific platform, and a proven management team.

ICO celebrates excellence in data protection with third annual award for practitioners

Retrieved on: 
Tuesday, February 4, 2020
Data protection, Privacy, CD278, Icos, Information privacy, Law, Social issues, Information

The call comes as applications open for the third annual Practitioner Award for Excellence in Data Protection.

Key Points: 
  • The call comes as applications open for the third annual Practitioner Award for Excellence in Data Protection.
  • Previous awards have gone to data protection practitioners who have shown outstanding impact in relation to accountability and inspired public trust and confidence in how personal information was handled.
  • I look forward to announcing the third recipient of the award at our Data Protection Practitioners Conference on 6 April in Manchester.
  • The winner will be announced at the ICOs Data Protection Practitioners Conference on 6 April 2020.

Alpine Immune Sciences Announces Poster Presentation at 2020 Crohn’s & Colitis Congress

Retrieved on: 
Monday, January 6, 2020
Biotechnology, Science, Health, Research, Medical specialties, Medicine, Immunology, Clinical medicine, Immunotherapy, CD278, Autoimmunity, Co-stimulation, T cell, ALPN-101, Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2020 Crohns & Colitis Congress taking place January 23-25, 2020, in Austin, Texas.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2020 Crohns & Colitis Congress taking place January 23-25, 2020, in Austin, Texas.
  • CD28 and ICOS are closely-related costimulatory molecules with partially overlapping roles in T cell activation likely playing a role in multiple autoimmune and inflammatory diseases.
  • Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics, creating potentially powerful multifunctional immunotherapies to improve patients lives via unique protein engineering technologies.
  • Alpine is backed by world-class research and development capabilities, a highly-productive scientific platform, and a proven management team.

Alpine Immune Sciences Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at the 61st American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 9, 2019
Biotechnology, Pharmaceutical, Health, Oncology, Medical specialties, Medicine, Immunology, Transplantation medicine, Immune system, CD278, Graft-versus-host disease, CD28, CD80, Icos, Co-stimulation, T cell, Graft Versus Host Disease (GVHD), ALPN-101, Alpine Immune Sciences, Inc.

T cell costimulation via the CD28 and ICOS pathways is critical to the pathogenesis of GVHD.

Key Points: 
  • T cell costimulation via the CD28 and ICOS pathways is critical to the pathogenesis of GVHD.
  • It exhibits a potent, unique activity superior to combinations of biologics individually antagonizing the CD28 CD80/86 and ICOS ICOSL pathways.
  • BALANCE is a Phase 1/2, first-in-disease dose escalation and expansion study of ALPN-101 in patients with active, steroid-refractory or steroid-resistant acute GVHD.
  • CD28 and ICOS appear to be key pathways in the pathogenesis of GVHD, and the presented data with ALPN-101 appear uniquely strong.

Jounce Therapeutics to Present Safety and Preliminary Efficacy Data on JTX-4014 and a Trials in Progress Poster for the Vopratelimab EMERGE Study at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting

Retrieved on: 
Tuesday, November 5, 2019
Bristol-Myers Squibb, Ipilimumab, CD278

The EMERGE trial builds on the biology of induction of ICOS hi CD4 T cells by ipilimumab and their expansion and sustained activation by vopratelimab.

Key Points: 
  • The EMERGE trial builds on the biology of induction of ICOS hi CD4 T cells by ipilimumab and their expansion and sustained activation by vopratelimab.
  • In a separate poster at SITC, the safety and preliminary efficacy data for JTX-4014 being presented supports the use of this PD-1 inhibitor in combination with our other product candidates.
  • Jounce researchers describe the safety, preliminary efficacy and recommended Phase 2 doses for JTX-4014 including:
    Acceptable safety profile for JTX-4014 based on a 6-cohort dose-escalation trial.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

Alpine Immune Sciences Announces Upcoming Scientific Presentations at SITC and ACR/ARHP 2019 Annual Meetings

Retrieved on: 
Wednesday, October 2, 2019
Research, General Health, Pharmaceutical, Oncology, Science, Clinical trials, Biotechnology, Other Science, Health, Medical specialties, Medicine, Immunology, Immune system, CD278, T cell, CD28, Checkpoint inhibitor, Autoimmunity

Alpine has two lead programs.

Key Points: 
  • Alpine has two lead programs.
  • The first, ALPN-101 for autoimmune/inflammatory diseases, is a selective dual T-cell costimulation blocker engineered to reduce pathogenic T and B cell immune responses by blocking ICOS and CD28..
  • The second, ALPN-202 for cancer, is a conditional CD28 costimulator and dual checkpoint inhibitor.
  • Alpine is backed by world-class research and development capabilities, a highly-productive scientific platform, and a proven management team.

ICO’s access to information strategy calls for better compliance by public authorities backed up with enforcement action

Retrieved on: 
Saturday, July 6, 2019
Articles, Business, Economy, Freedom of information in the United Kingdom, Eli Lilly and Company, Icos, Freedom of Information Act, CD278, Elizabeth Denham, Freedom of information laws by country, Environmental Information Regulations, Access to information

The ICO has today published ‘Openness by Design’ , its new access to information strategy.
The strategy sets out five goals relating to the suite of access to information legislation regulated by the ICO: Freedom of Information Act (FOIA) 2000, the Environmental Information Regulations (EIR)…

Key Points: 
  • The strategy sets out five goals relating to the suite of access to information legislation regulated by the ICO: Freedom of Information Act (FOIA) 2000, the Environmental Information Regulations (EIR) 2004, and the Re-use of Public Sector Information Regulations 2015.
  • The five Openness by Design goals are:

    The ICOs ambition is to increase the impact of its regulation of access to information legislation.

  • Elizabeth Denham, Information Commissioner said:

    The strategy commits to continue to promote the reform of access to information laws as set out in the ICOs Outsourcing Oversight?

  • The strategy, which runs until 2022, will be continually assessed to ensure it aligns with the ICOs Information Rights Strategic Plan.

Bill Poulos, President of Profits Run, Inc., Revealed The Top ICOs To Watch For In July 2018 While Reviewing Previously Successful Cryptocurrencies

Retrieved on: 
Tuesday, July 10, 2018
Eli Lilly and Company, Icos, CD278, Cryptocurrency, International Council of Onomastic Sciences, Poulos, Economy, Finance, Culture, Initial coin offering

Last week (July 5, 2018), Poulos published the article, "5 Next Best ICO Opportunities To Look Out For."

Key Points: 
  • Last week (July 5, 2018), Poulos published the article, "5 Next Best ICO Opportunities To Look Out For."
  • In the investing.com article, Poulos broke down the five ICOs to watch, the potential value the companies could add to the world, and reviewed past ICOs that were successful.
  • Bill explained this is "where investors traded in sums of their existing cryptocurrency to give life to brand new tokens."
  • Poulos revealed that the top five ICOs to look for are Uchain, Deepcloud AI, DxChain, ANKR Network, and Cognida.

Social Impact Investor David Drake Joins Genetic Immunity's Dermavir ICO Advisory Board to Fight Infectious Diseases

Retrieved on: 
Thursday, April 19, 2018
Economy, Technology, Money, Cryptocurrencies, Initial coin offering, Icos, HIV vaccine, CD278, Vaccine, Crowdfunding, International Council of Onomastic Sciences

David has extensive expertise in media, initial coin offerings, and in the crowdfunding space.

Key Points: 
  • David has extensive expertise in media, initial coin offerings, and in the crowdfunding space.
  • "I'm very excited to bring my extensive network and experience in ICOs, media and publicity to support the launch of Dermavir, a Phase II HIV vaccine development," says David.
  • In the past 9 months, the top 15 ICOs that David has been advising have raised over USD 500,000,000.
  • Our technology is designed to boost specific immune response in order to modify or control presently incurable diseases.